Challenges in radiobiology - technology duality as a key for a risk-free α/β ratio.

Bull Cancer

Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS5822/IP2I, Université de Lyon, Lyon 1 University, 69921 Oullins, France; Université de Lyon, Lyon 1 University, UMR CNRS5822/IP2I, 69100 Villeurbanne, France; Institut Bergonié, Department of Radiation Oncology, 33076 Bordeaux, France.

Published: June 2023

Since radiotherapy discovery, prediction of biological response to ionizing radiation remains a major challenge. Indeed, several radiobiological models appeared through radiotherapy history. Nominal single dose so popular in the 1970s, was tragically linked to the dark years in radiobiology by underestimating the late toxicity of the high-dose fractions. The actual prominent linear-quadratic model continues to prove to be an effective tool in radiobiology. Mainly with its pivotal α/β ratio, which gives a reliable estimate of tissues sensitivity to fractions. Despite these arguments, this model experiences limitations with substantial doubts of α/β ratio values. Interestingly, the story of radiobiology since X-ray discovery is truly instructive and teaches modern clinicians to refine fractionation schemes. Many fractionation schemes have been tested with successes or dramas. This review retraces radiobiological models' history, and confronts these models to new fractionation schemes, drawing a preventive message.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2023.02.006DOI Listing

Publication Analysis

Top Keywords

α/β ratio
12
fractionation schemes
12
challenges radiobiology
4
radiobiology technology
4
technology duality
4
duality key
4
key risk-free
4
risk-free α/β
4
ratio radiotherapy
4
radiotherapy discovery
4

Similar Publications

Article Synopsis
  • * A systematic review and Bayesian network meta-analysis were conducted, analyzing existing randomized controlled trials (RCTs) to evaluate the efficacy and safety of these two drugs at Week 24.
  • * The results indicated no significant difference in hair regrowth effectiveness between ritlecitinib and baricitinib, but highlighted the need for more research due to uncertainty and effect modifications found in the analysis.
View Article and Find Full Text PDF

The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consortium (MAGIC) transplant centers who achieved complete response (CR) or very good partial response (VGPR) within 4 weeks of treatment. The cumulative incidence of flares within 6 months was 22%, and flares were associated with a higher risk of nonrelapse mortality (NRM; adjusted hazard ratio [aHR], 4.

View Article and Find Full Text PDF

Tiron ameliorates acetic acid-induced colitis in rats: Role of TGF-β/EGFR/PI3K/NF-κB signaling pathway.

Int Immunopharmacol

February 2024

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. Electronic address:

Background: Ulcerative colitis (UC), an ongoing inflammatory disorder of the colon, is marked by persistent mucosal surface irritation extending from the rectum to the near-proximal colon. Tiron is a synthetic analogue of vitamin E which is known to have antioxidant and anti-inflammatory effects in various animal models, so the goal of this study was to find out whether Tiron had any preventive impacts on UC inflicted by acetic acid (A.A) exposure in rats.

View Article and Find Full Text PDF

Importance: Baricitinib is an oral selective Janus kinase 1/2 inhibitor that has achieved clinically meaningful outcomes for scalp, eyebrow, and eyelash hair regrowth in patients with severe alopecia areata (AA) at week 36 of treatment. Treatment with baricitinib, 4 mg, has resulted in higher response rates than baricitinib, 2 mg, at weeks 36 and 52.

Objective: To determine the efficacy of uptitration to baricitinib, 4 mg, for 24 weeks in patients who had previously not responded to baricitinib, 2 mg (Severity of Alopecia Tool [SALT] score of >20).

View Article and Find Full Text PDF
Article Synopsis
  • The study presents an experimental demonstration of an optics-based half-adder that processes two channels of 4-phase-shift-keying (4-PSK) data using nonlinear wave mixing technology.
  • The system takes two sets of 4-ary phase-encoded inputs and produces corresponding outputs labeled as Sum and Carry through a nonlinear device, showcasing multiple phase levels for both inputs and outputs.
  • Experimental findings indicate that the half-adder achieves specific conversion efficiencies for data outputs, with low optical signal-to-noise ratio penalties at varying symbol rates, confirming its effectiveness in high-speed optical communication.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!